StockNews.AI
TMO
StockNews.AI
3 hrs

Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases

1. TMO announces $5 billion share repurchase program with no expiration date. 2. This move aims to enhance shareholder value over time. 3. TMO has annual revenue of approximately $40 billion. 4. The company's diverse brands support life sciences and diagnostics. 5. Strategic buybacks can positively influence TMO’s stock price.

5m saved
Insight
Article

FAQ

Why Very Bullish?

Share buybacks typically indicate confidence in company value and can reduce share supply, driving prices up. Historical examples include Apple’s buyback programs, which led to significant price increases post-announcement.

How important is it?

A large buyback can indicate strong management confidence in future growth, making it highly relevant to TMO’s stock outlook.

Why Long Term?

The ongoing repurchase can support TMO's stock price over time, enhancing its value per share, much like other successful repurchase strategies used by major companies.

Related Companies

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media Contact Information:

Sandy Pound

781-622-1223

sandy.pound@thermofisher.com

Investor Contact Information:

Rafael Tejada

781-622-1356

rafael.tejada@thermofisher.com

Related News